Industry News
Company Expects Phase 2 Data with Second Drug Candidate (CST-103) in Neurodegenerative Diseases in Third Quarter of 2022 Excerpt from the Press Release: SAN CARLOS, Calif.–(BUSINESS WIRE)–CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032,…
Read More
— Company Expects to Announce Topline Data from Study in Adults 65 Years and Older in the First Half of 2023 — — Vaxcyte Remains on Track to Announce Topline Data from the Phase 1 and Phase 2 Portions of the VAX-24 Proof-of-Concept Study in Adults Aged 18-64 in October or November 2022 — —…
Read More
Expected to Accelerate Sales Opportunities in Doctor’s Office and Wound Clinics Excerpt from the Press Release: FRAMINGHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that it has launched a multi-site clinical study…
Read More
Data published in bioRxiv shows ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes in mice and non-human primates (NHPs) Prime-boost administration of ELI-005 induced potent Spike receptor binding domain (RBD)-specific effector cytokine-producing T cell responses in mouse and NHP peripheral blood showing cross-reactivity against variants…
Read More
Study’s Results Reveal CBC’s Robust Therapeutic Properties to Help Contribute to Skin Health Excerpt from the Press Release: SAN FRANCISCO, Sept. 8, 2022 /PRNewswire/ — Purissima, a leading biotechnology health and wellness company, announced the completion of two separate ingredient testing programs with two leading contract research organizations. Testing included biological tests on human skin…
Read More
– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab – – Median progression-free survival was not yet reached with the combination of cabozantinib, nivolumab and ipilimumab versus 11.3 months with nivolumab combined with ipilimumab – Excerpt from the Press…
Read More
ALM-488 is a peptide-dye conjugate designed to fluorescently highlight nerves in real time during surgery Excerpt from the Press Release: LA JOLLA, Calif., Aug. 23, 2022 /PRNewswire/ — Alume Biosciences, Inc, a leader in the field of nerve-targeted diagnostics and therapeutics, today announced that the first patient has been dosed in a Phase 3 pivotal…
Read More
Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple myeloma (MM). BMF-219 displayed single agent potency, surpassing greater than 90% inhibition at clinically relevant exposures in both DLBCL and MM cell lines and patient-derived samples. A Trial…
Read More
– 141 MDS Patients Enrolled –– Topline Data Anticipated 1H:2023 – Excerpt from the Press Release: SAN FRANCISCO, Aug. 26, 2022 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for MATTERHORN, a Phase 3 clinical study of roxadustat for treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS).…
Read More
Preclinical data showed synergistic and additive effects of combination imetelstat and ruxolitinib Study intended to explore potential for disease modification with imetelstat in earlier, frontline myelofibrosis setting Single-agent imetelstat currently being studied in a separate Phase 3 trial designed to confirm clinically meaningful benefits observed in relapsed/refractory MF patients in Phase 2 study Excerpt from…
Read More